Evidence-based Series 1-12: ARCHIVED 2014

A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO)

The Role of Gemcitabine in the Management of Metastatic Breast Cancer

Members of the Breast Cancer Disease Site Group

An assessment conducted in January 2014 ARCHIVED Evidence-based Series (EBS) 1-12. This means that the recommendations will no longer be maintained but may still be useful for academic or other information purposes.

EBS 1-12: TO BE UPDATED is comprised of the following 4 sections:
1. Guideline Report Overview
2. Section 1: Guideline Recommendations
3. Section 2: Systematic Review
4. Section 3: EBS Development Methods and External Review Process
5. Document Assessment and Review Tool

and is available on the CCO Web site (http://www.cancercare.on.ca)
PEBC Breast Cancer DSG page at:
http://www.cancercare.on.ca/toolbox/qualityguidelines/diseasesite/breast-ebs/

Release Date: September 15, 2011

For information about the PEBC and the most current version of all reports, please visit the CCO at http://www.cancercare.on.ca/ or contact the PEBC office at:
Phone: 905-527-4322 ext. 42822   Fax: 905-526-6775   E-mail: ccopgi@mcmaster.ca

Citation (Vancouver Style): Members of the Breast Cancer Disease Site Group. The role of gemcitabine in the management of metastatic breast cancer. Dent S, Tey R, reviewers. Toronto (ON): Cancer Care Ontario; 2011 Sep 15 [To be updated]. Program in Evidence-based Care Evidence-Based Series No.: 1-12 ARCHIVED 2014
# Table of Content

**Overview**
- Guideline Report History ................................................................. iii
- Guideline Review Summary ................................................................. iv

**SECTION 1: Guideline Recommendations**
- Key Evidence .................................................................................. 1
- Guideline Question ........................................................................... 1
- Recommendations ............................................................................. 1
- Qualifying Statements ...................................................................... 2
- Funding, Copyright, Disclaimer, & Contact Information .................. 3
- References ......................................................................................... 4

**SECTION 2: Systematic Review**
- Question .......................................................................................... 1
- Introduction ......................................................................................... 1
- Methods .............................................................................................. 2
- Results ................................................................................................. 3
- Discussion ........................................................................................... 8
- Ongoing trials ..................................................................................... 9
- Conclusions ......................................................................................... 10
- Conflict of Interest ............................................................................. 10
- Journal Reference .............................................................................. 10
- Acknowledgements ............................................................................ 10
- Funding, Copyright, Disclaimer, & Contact Information ................ 10
- References .......................................................................................... 12
- Appendix 1. Summary of results of non-randomized trials .......... 20

**SECTION 3: EBS Development Methods and External Review Process**
- Program in Evidence-based Care ...................................................... 1
- Development of this EBS ................................................................. 2
- Funding, Copyright, Disclaimer, & Contact Information ................. 6
- References ......................................................................................... 7
- EBS 1-12 Document Assessment and Review Tool ......................... 9
Evidence-based Series 1-12: TO BE UPDATED

The Role of Gemcitabine in the Management of Metastatic Breast Cancer

Guideline Report History

<table>
<thead>
<tr>
<th>GUIDELINE VERSION</th>
<th>SYSTEMATIC REVIEW</th>
<th>PUBLICATIONS</th>
<th>NOTES AND KEY CHANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original version</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jun 2006</td>
<td>1966 to 2005</td>
<td>Full Report</td>
<td>Peer review publication Web publication Not Applicable (NA)</td>
</tr>
<tr>
<td>Update</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan 2007</td>
<td>2005 to 2006</td>
<td>New data added to original Full Report</td>
<td>Updated Web publication NA</td>
</tr>
<tr>
<td>Reviewed version</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sep 2011</td>
<td>2006 to 2010</td>
<td>New data found in Document Assessment and Review Tool</td>
<td>2007 Recommendations require an UPDATE</td>
</tr>
</tbody>
</table>

Evidence-based Series 1-12 TO BE UPDATED

The Role of Gemcitabine in the Management of Metastatic Breast Cancer

Guideline Review Summary

Review Date: November 19, 2010

The 2007 guideline recommendations require UPDATE

This means that the DSG/GDG will rewrite the guideline at the earliest opportunity. Until then the recommendations remain of some use in clinical decision making.

OVERVIEW
Evidence-based Series History
This guidance document was originally released by the Program in Evidence-based Care, Cancer Care Ontario, in 2006 and its first update released in January 2007. In November 2010, the PEBC guideline update strategy was applied, and it was determined that the document needs to be updated. The Practice Guideline and Systematic Review in this version are the same as in the January 2007 version.

Update Strategy
Using the Document Assessment and Review Tool, the PEBC update strategy includes an updated search of the literature, review and interpretation of the new eligible evidence by clinical experts from the authoring guideline panel, and consideration of the guideline and its recommendations in response to the new available evidence.

DOCUMENT ASSESSMENT AND REVIEW RESULTS
Questions Considered
- What is the role of gemcitabine, alone or in combination, as first-line chemotherapy in women with metastatic breast cancer?
- What is the role of gemcitabine, alone or in combination, as second-line or greater chemotherapy in women with metastatic breast cancer?
Literature Search and New Evidence

The new search (October 2006 to August 2010) yielded 16 relevant publications (nine abstracts and five full text publication) from 13 RCTs. Initial publications of two randomized controlled trials (RCTs) were already included in the original document. Brief results of these publications are shown in the Document Assessment and Review Tool at the end of this report.

Impact on Guidelines and Its Recommendations

The new data supports the existing recommendations but the current recommendations do not cover all relevant subjects. The newly identified evidence introduces targeted therapies in combination with chemotherapy (e.g., bevacizumab and platinum). Hence, the Breast Cancer DSG decided that the 2007 recommendations on the role of gemcitabine in the management of metastatic breast cancer require an UPDATE.
Evidence-based Series 1-12: Section 1

The Role of Gemcitabine in the Management of Metastatic Breast Cancer: A Clinical Practice Guideline

S. Dent, H. Messersmith, M. Trudeau, and the Breast Cancer Disease Site Group

A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO)

Please see the EBS 1-12 Guideline Review Summary and the Document Assessment and Review Tool for the summary of updated evidence published between 2006 and 2010.

Report Date: January 22, 2007

Question
- What is the role of gemcitabine, alone or in combination, as first-line chemotherapy in women with metastatic breast cancer?
- What is the role of gemcitabine, alone or in combination, as second-line or greater chemotherapy in women with metastatic breast cancer?

Target Population
Women with metastatic breast cancer.

Recommendations and Key Evidence

The combination of gemcitabine and docetaxel may be considered as an alternative to capecitabine and docetaxel for first- or second-line chemotherapy in patients where the toxicity of the capecitabine and docetaxel regimen is a concern.

- One randomized phase III study reported by Chan et al in abstract form (1,2) found no significant difference between the combination of gemcitabine (1000 mg/m² on days one and eight) and docetaxel (75 mg/m² on day one) every 21 days and the combination of capecitabine (1250 mg/m² twice a day for 14 days) and docetaxel (as above) every 21 days in terms of objective response rate (ORR), progression-free survival (PFS), duration of response, or time-to-progression (TTP). However, patients receiving gemcitabine plus docetaxel experienced significantly less hand-foot syndrome, diarrhea, and mucositis than those receiving capecitabine plus docetaxel.
Qualifying Statements

- The efficacy of capecitabine and docetaxel over docetaxel alone was demonstrated in a trial by O'Shaughnessy et al (3) but the clinical utility of this regimen has been hampered by significant toxicities, especially hand-foot syndrome and mucositis.

For patients with metastatic breast cancer who have received prior (neo)adjuvant anthracycline therapy, the combination of gemcitabine plus paclitaxel is superior compared to paclitaxel alone as first-line chemotherapy.

- A randomized controlled trial reported at the 2003 and 2004 American Society of Clinical Oncology (ASCO) meetings (4-9) compared the combination of gemcitabine (1250 mg/m² of on days one and eight) and paclitaxel (175 mg/m² on day one) every 21 days to the same dosage and schedule of paclitaxel without gemcitabine in patients with metastatic breast cancer who had previously received adjuvant or neoadjuvant anthracycline chemotherapy. That trial found a significantly superior ORR (40.8% versus 22.1%, p<0.0001), median TTP (5.2 months versus 2.9 months, hazard ratio [HR] 0.650, 95% confidence interval [CI] 0.524 to 0.805), and overall survival (18.5 months versus 15.8 months, HR 0.775, 95% CI 0.627 to 0.959) in patients treated with the combination regimen.

Qualifying Statements

- Patients who received the combination regimen experienced a higher rate of neutropenia (48% versus 11%) over those treated with paclitaxel alone.
- The clinical relevance of this regimen in Ontario is questionable as docetaxel has been the standard taxane used in the metastatic setting.

Single-agent gemcitabine is NOT recommended for women with metastatic breast cancer who are being considered for first-line single-agent anthracycline chemotherapy.

The combination of gemcitabine, epirubicin, and paclitaxel (GET) is NOT recommended as first-line chemotherapy for women with metastatic breast cancer who are being considered for anthracycline-based combination chemotherapy.

- One randomized phase III study reported by Feher et al in (10) compared epirubicin (35 mg/m² on days one, eight, and 15) with gemcitabine (1200 mg/m² on days one, eight, and 15) every 28 days in postmenopausal patients aged 60 or older. No significant differences were found between the treatment arms in terms of time to response and duration of response. Epirubicin was significantly better than gemcitabine in terms of ORR (40.3% versus 16.4%, p<0.0001), TTP (6.1 months versus 3.4 months, p=0.0001), and overall survival (19.1 months versus 11.8 months, p=0.004).
- A randomized controlled trial reported by Zielinski et al (11) compared the combination of gemcitabine (1000 mg/m² on days one and four), epirubicin (90 mg/m² on day one), and paclitaxel (175 mg/m² on day one), with the combination of 5-fluorouracil (500 mg/m²), epirubicin (90 mg/m²), and cyclophosphamide (500 mg/m²), all on day one. Both combinations used a 21-day cycle. Patients were required to have had one prior non-anthracycline adjuvant chemotherapy. That trial found no significant differences in terms of ORR, TTP, or overall survival and found significantly higher haematological toxicities, polyneuropathy, and mucositis in the gemcitabine-containing arm.

Qualifying Statements

- Doxorubicin given as a single agent or in combination is currently approved and funded for women with metastatic breast cancer in Ontario. Epirubicin-based combinations are not funded for women with metastatic breast cancer in Ontario.
Funding
The PEBC is supported by Cancer Care Ontario (CCO) and the Ontario Ministry of Health and Long-Term Care. All work produced by the PEBC is editorially independent from its funding agencies.

Copyright
This evidence-based series is copyrighted by Cancer Care Ontario; the series and the illustrations herein may not be reproduced without the express written permission of Cancer Care Ontario. Cancer Care Ontario reserves the right at any time, and at its sole discretion, to change or revoke this authorization.

Disclaimer
Care has been taken in the preparation of the information contained in this document. Nonetheless, any person seeking to apply or consult the evidence-based series is expected to use independent medical judgment in the context of individual clinical circumstances or seek out the supervision of a qualified clinician. Cancer Care Ontario makes no representation or guarantees of any kind whatsoever regarding their content or use or application and disclaims any responsibility for their application or use in any way.

Contact Information
For further information about this series, please contact Dr. Maureen Trudeau, Co-Chair, Breast Cancer Disease Site Group, Toronto-Sunnybrook Regional Cancer Centre, 2075 Bayview Ave, Toronto ON, M4N 3M5; (416) 480-5145; FAX (416) 480-6002.

For information about the PEBC and the most current version of all reports, please visit the CCO at http://www.cancercare.on.ca/ or contact the PEBC office at:
Phone: 905-527-4322 ext. 42822   Fax: 905-526-6775   E-mail: ccopgi@mcmaster.ca
REFERENCES


